Affiliation:
1. Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ
Abstract
Abstract
This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. This review focuses on clinical trial data leading to drug approval and provides advice for treating physicians who are now accessing this drug for patients.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference79 articles.
1. Proteasome inhibition as a novel therapeutic target in human cancer.;Rajkumar;J Clin Oncol,2005
2. A phase 2 study of bortezomib in relapsed, refractory myeloma.;Richardson;N Engl J Med,2003
3. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.;Richardson;J Clin Oncol,2006
4. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.;Moreau;Lancet Oncol,2011
5. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.;Bringhen;Blood,2010
Cited by
187 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献